Table 3.

Risk of hospitalization, intensive care, and death in ASCT-patients versus the general population.

Age group, years	Cases	Hospitalized, n (%)	ICU, n (%)	Death, n (%)
40–49
Sweden	148,656	5,817 (3.91)	614 (0.41)	90 (0.06)
Study cohort	5	1 (20)	0	0
50–59
Sweden	133,053	9,468 (7.13)	1,383 (1.04)	329 (0.25)
Study cohort	2	1 (50)	0	0†
60–69
Sweden	69,354	10,582 (15.26)	1,890 (2.73)	854 (1.23)
Study cohort‡	10	4 (40)	2 (20)	3 (27)§
Total (40–69)
Sweden	351,063	25,885 (7.37) (CI: 7.29–7.46)	3,887 (1.11) (CI: 1.07–1.14)	1,273 (0.36) (CI: 0.34–0.38)
Study cohort	17	6 (35) (CI: 17.3–58.7)	2 (12) (CI: 3.29–34.3)	3 (15) (CI: 5.24–36.0)¶

The table shows the risk of hospitalization, need for ICU, and death following infection with SARS-CoV-2 in the Swedish general population and the study cohort of patients treated with ASCT for hematological malignancy. The percentages shown are compared with the total number of cases for the row. Data from the public health agency of Sweden.

^†Mortality data available for four patients in the 50–59 cohort.

^‡One patient was 70 years and 1 month at the time of infection.

^§Mortality data available for 11 patients in the 60–69 years cohort.

^¶Mortality data available for all 20 patients.

Bold numbers indicate total cases of COVID-19 for each row and each column in Sweden and in the study cohort.